ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersa's distinguished group of Scientific AdvisorsVAR 200 is a phase 2a-ready cholesterol e...

Related Keywords

Miami ,Florida ,United States ,Toronto ,Ontario ,Canada ,Michigan ,Alessia Fornoni ,Danielc Cattran ,Sharong Adler ,Fernandoc Fervenza ,Debbies Gipson ,Stephenc Glover ,Pabloa Guzman ,Pablo Guzman ,Marlene Haffner ,Division Of Nephrology ,Nasdaq ,University Of Toronto ,Founder Of Orphan Solutions ,Products Development ,Department Of Pediatrics At University Michigan ,Katz Family Division Of Nephrology ,Nephrology Fellowship Training Program At ,Prnewsfoto Variant Pharmaceuticals Inc ,Prnewswire Zyversa Therapeutics Inc ,Kidney Research Network Coordinating Center ,Mayo Graduate School Of Medicine ,Nephrology Collaborative Group ,Zyversa Therapeutics Inc ,University Of Miami Miller School Medicine ,Research Institute ,Securities Exchange ,Versa Therapeutics ,Renal Scientific Advisory ,Variant Pharmaceuticals ,Renal Scientific Advisory Board ,Toronto General Research ,Mayo Graduate School ,Nephrology Collaborative ,Scientific Advisory Board ,Chief Medical Officer ,Scientific Advisors ,David Geffen School ,Program Director ,Nephrology Fellowship Training Program ,Katz Family Division ,Miami Miller School ,Orphan Solutions ,Orphan Products Development ,Chief Executive Officer ,Glover About ,Zyversa Therapeutics ,Securities Exchange Act ,Private Securities Litigation Reform Act ,